跳至主要内容
临床试验/NCT00159887
NCT00159887已完成3 期

A Multi-Centre, Multinational, Long-Term Extension Study, to Assess the Safety and Toleration of Subject Optimised Treatment Regimens of Oral Sildenafil Citrate for Pulmonary Arterial Hypertension in Subjects Who Have Completed Study A1481140.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.66 个研究点 分布在 16 个国家目标入组 260 人开始时间: 2002年12月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
260
试验地点
66
主要终点
Safety

研究概览

简要总结

Open label extension study to the pivotal efficacy study to assess the safety of sildenafil citrate in patients with pulmonary arterial hypertension

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with PAH who had completed the 12 week pivotal study

排除标准

  • Any other patients with PAH that had not been included into the pivotal study

结局指标

主要结局

Safety

Standard safety data

Efficacy

BORG Dyspnoea Score

6-Minute Walk Test

WHO Functional Class

Quality of Life SF-36 and EQ-5D

次要结局

未报告次要终点

研究者

发起方
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (66)

Loading locations...

相似试验